Heparin-induced thrombocytopenia cost-effectiveness of therapy
|
Heparin-induced thrombocytopenia |
|
Differentiating Heparin-induced thrombocytopenia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Heparin-induced thrombocytopenia cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Heparin-induced thrombocytopenia cost-effectiveness of therapy |
|
FDA on Heparin-induced thrombocytopenia cost-effectiveness of therapy |
|
CDC on Heparin-induced thrombocytopenia cost-effectiveness of therapy |
|
Heparin-induced thrombocytopenia cost-effectiveness of therapy in the news |
|
Blogs on Heparin-induced thrombocytopenia cost-effectiveness of therapy |
|
Directions to Hospitals Treating Heparin-induced thrombocytopenia |
|
Risk calculators and risk factors for Heparin-induced thrombocytopenia cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2], Aric C. Hall, M.D., [3], Shyam Patel [4]
Overview
Cost-Effectiveness of Therapy
The treatment of HIT involves use of alternative anticoagulants, such as direct thrombin inhibitors. However, there is also data for use of the factor X inhibitor fondaparinux, which is less expensive than direct thrombin inhibitors.[1] Fondaparinux would found to be the most cost-effective agent for treatment of HIT, compared to argatroban or bivalirudin. [1]
References
- ↑ 1.0 1.1 Aljabri A, Huckleberry Y, Karnes JH, Gharaibeh M, Kutbi HI, Raz Y; et al. (2016). "Cost-effectiveness of anticoagulants for suspected heparin-induced thrombocytopenia in the United States". Blood. 128 (26): 3043–3051. doi:10.1182/blood-2016-07-728030. PMID PMID27793877 Check
|pmid=value (help).